BioInsights - Development of lentiviral vector packaging and producer cell lines
Feb
16
2023
Upcoming webinar

Development of lentiviral vector packaging and producer cell lines

08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Development of lentiviral vector packaging and producer cell lines

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Lentiviral vectors (LVV) are of increasing interest in cell and gene therapy, but high costs and variable vector productions continue to limit patient access. LVV packaging and producer cell lines that yield titers as high as the four-plasmid method will reduce cost and process variability, as they rely less on plasmid transfection for production of LVV.

In this webinar, we will explore the initial development of an LVV packaging cell line by random integration of Tet-regulated VSV-G and Gag-Pol, and constitutive Rev (codon optimized and regions of DNA homology deleted to decrease risk of recombination) into clonal WXATUS0028 suspension HEK 293 cell line, followed by clonal isolation of the top performing clone. Subsequently, we developed an LVV producer cell line by transposon-facilitated integration of LVV genome into our top packaging cell line clone, followed by clonal isolation of the top performing clone. We will also describe trialed production of LVV encoding several different therapeutically relevant transgenes. 

Attend this webinar to find out how to:

  • Address key issues associated with transient systems, including high costs and variable yields
  • Achieve LVV titers with production cell lines that are comparable to the industry standard four-plasmid method, ultimately improving patient access to LVV-based cell and gene therapies

Matthew Tridgett, PhD

Senior Scientist, Viral Cell Line Development, OXGENE, a WuXi Advanced Therapies Company

Matt is a Senior Scientist in the Viral Cell Line Development group at OXGENE, working on the development of lentiviral producer cell lines. Before joining OXGENE, Matt was a Postdoctoral Research Scientist at the University of Warwick, where he worked on the development of a bacteriophage-based combination vaccine/antibacterial. Matt completed his PhD in Biotechnology and BSc in Biochemistry at the University of Birmingham.

9
Days

SPEAKERS

Matthew Tridgett, PhD
Matthew Tridgett, PhD
Senior Scientist, Viral Cell Line Development, OXGENE, a WuXi Advanced Therapies Company

You might also like